Novel Genes Could Serve as Predictive Biomarkers for PARP Inhibitor Response in Prostate Cancer

Prostate cancer tumors harboring BRCA1/2 mutations are exceptionally sensitive to PARP inhibitors, while genomic alterations in other DNA damage response (DDR) genes are less responsive. To identify previously unknown genes whose loss has a profound impact on PARP inhibitor response, researchers from Dana-Farber Brigham Cancer Center led a multinational effort to perform genome-wide CRISPR-Cas9 knockout screens. The study goal was to inform the use of PARP inhibitors beyond BRCA1/2-deficient tumors and support reevaluation of current biomarkers for PARP inhibition in prostate cancer.

The study identified multiple novel genes (e.g., MMS22L and RNASEH2B) that are frequently deleted in prostate cancer. These genes could serve as predictive biomarkers for PARP inhibitor response in prostate cancer, according to the study. The research team also found that loss of CHEK2 (the FDA-approved biomarker for therapeutic response to olaparib) confers resistance, rather than sensitivity, to PARP inhibition.

Current targeted cancer therapies, including PARP inhibitors, are largely guided by mutations of a single gene and overlook concurrent genomic alterations. We found that PARP inhibitor sensitivity instead may depend on interaction between multiple genomic alterations. Therefore, comprehensive genomic analysis may help improve clinical decision making."

Li Jia, PhD, Director of Urology Research, Brigham and Women's Hospital

Source:
Journal reference:

Tsujino, T., et al. (2023). CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature Communications. doi.org/10.1038/s41467-023-35880-y.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Bioinformatics Tool Recognizes Chromosome Changes in Cancer Cells